The overall goals of the Early Detection Research Network (EDRN) are to: a) identify biomarkers for cancer risk, early detection, molecular diagnostics, and prognosis of early cancer;and b) coordinate biomarker research and therapeutic strategies in order to reduce cancer morbidity and mortality. As a Clinical Validation Center (CVC), Fox Chase Cancer Center (FCCC) will: 1) maintain the FCCC multidisciplinary team of biomarker validation investigators;2) comply with terms and conditions of the EDRN cooperative agreement including data sharing;3) partner with EDRN Biomarker Development Labs (BDLs), Biomarker Reference Labs (BRLs), CVCs, and the Data Management and Coordination Center (DMCC);4) participate in EDRN Steering Committee and Scientific meetings and activities and the EDRN Breast/Ovarian Cancer Consortium Group;5) collect, store and distribute tissue, sera, and DNA for biomarker discovery and validation research especially from women at risk for breast and ovarian cancer;6) partner with Geisinger Medical Center to develop population-based biomarker research validation studies. FCCC-EDRN-CVC proposes an investigator-initiated proteomic and DNA methylation phase II biomarker validation research project in women with benign breast disease (BBD) who are at risk for invasive cancer. This research utilizes biosamples collected during the past five years of EDRN funding.
The aims are as follows: Study 1, Validation of candidate proteomic biomarker in BBD.
Aim 1, verify that protein biomarker can distinguish preca-ncer lesions;
Aim 2, validate proteomic biomarker in a set of well annotated clinical specimens. Study 2 Validations of Hypermethylated Markers.
Aim 1, verify gene methylation for risk stratification in BBD;
Aim 2, develop a serum-based assay in women with BBD. Numerous collaborators in and outside EDRN will utilize the FCCC-EDRN-CVC large annotated collection of breast and ovarian benign and cancer sera, DNA, and tissue samples. The proposed validation study is focused on BBD and investigates protein and DNA methylation in the same cases. The FCCC EDRN-CVC will help to translate biomarker research to community practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01CA113916-09
Application #
8505393
Study Section
Special Emphasis Panel (ZCA1-SRLB-3 (M1))
Program Officer
Patriotis, Christos F
Project Start
2005-03-21
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$691,275
Indirect Cost
$283,630
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Serrero, Ginette; Hawkins, Douglas M; Bejarano, Pablo A et al. (2016) Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index. Diagn Pathol 11:71
Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2016) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat :
(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
Silvestri, Valentina; Barrowdale, Daniel; Mulligan, Anna Marie et al. (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 18:15
Blein, Sophie; Bardel, Claire; Danjean, Vincent et al. (2015) An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 17:61
Alturkmani, Hani J; Pessetto, Ziyan Y; Godwin, Andrew K (2015) Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opin Investig Drugs 24:1045-58
Blanco, Ignacio; Kuchenbaecker, Karoline; Cuadras, Daniel et al. (2015) Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10:e0120020
Marks, Jeffrey R; Anderson, Karen S; Engstrom, Paul et al. (2015) Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev 24:435-41

Showing the most recent 10 out of 51 publications